Source comparison
PT-141 vs Appetite-Targeting Peptides: Mechanism Comparison
PT-141 (Bremelanotide) MC3R/MC4R agonist. Activates melanocortin pathways in hypothalamus 90–120 minutes post-dose 4–6 hours Non-selective (MC3R and MC4R equally) Valuable research tool for melanocortin appetite pathways; not optimized for weight management du
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist. Activates melanocortin pathways in hypothalamus
- 90–120 minutes post-dose
- 4–6 hours
- Non-selective (MC3R and MC4R equally)
- Valuable research tool for melanocortin appetite pathways; not optimized for weight management due to short half-life and dual receptor activation
- Setmelanotide (Imcivree)
- MC4R-selective agonist. Targets satiety signaling specifically
- 60–90 minutes post-dose
- 8–12 hours
- Highly selective (MC4R > 80-fold over MC3R)
- FDA-approved for genetic obesity (POMC/LEPR deficiency); superior duration and selectivity make it clinically viable for appetite control
- Semaglutide (Wegovy)
- GLP-1 receptor agonist. Slows gastric emptying, extends postprandial incretin signaling
- 24–48 hours (accumulates over weeks)
- Continuous at therapeutic dose
- GLP-1R-specific
- Gold standard for pharmacological weight loss; 14.9% mean body weight reduction in STEP-1 trial; weekly dosing maintains steady-state appetite suppression
- Tirzepatide (Mounjaro)
- Dual GIP/GLP-1 agonist. Combines incretin effects with enhanced insulin sensitivity
- 48–72 hours (accumulates over weeks)
- GIP and GLP-1 receptors
- Superior to semaglutide in head-to-head trials (SURMOUNT-1: 20.9% weight loss at 15mg weekly); dual agonism produces additive metabolic benefits
- GHRP-2
- Growth hormone secretagogue. Stimulates GH release, increases ghrelin signaling
- 30–60 minutes post-dose
- 2–3 hours
- Ghrelin receptor agonist (orexigenic. Increases appetite)
- Opposite effect to PT-141; used in research to understand hunger signaling and GH-ghrelin interactions; not for appetite suppression
- PT-141 help appetite control research by revealing melanocortin receptor dynamics, but clinical appetite suppression requires receptor selectivity, pharmacokinetic stability, and sustained target engagement. Qualities PT-141 lacks but setmelanotide and GLP-1 agonists possess. The comparison underscores why PT-141 remains a research tool rather than a therapeutic option for weight management.